<DOC>
	<DOCNO>NCT01176461</DOCNO>
	<brief_summary>This pilot phase 1 , open-label , single center , multi-dose , dose-escalation study BMS-936558 combination without peptide vaccine . The purpose study test side effect investigational vaccine immune booster . Investigators also wish find effect patient 's immune system whether shrink melanoma .</brief_summary>
	<brief_title>Multiple Class I Peptides &amp; Montanide ISA 51 VG w Escalating Doses Anti-PD-1 ab BMS936558</brief_title>
	<detailed_description>BMS-936558 administer i.v . infusion , use volumetric pump 0.2 micron in-line filter protocol-specified dose ( ) rate . The vaccine consist follow peptide : gp100280-288 ( 288V ) , NY-ESO-1157-165 ( 165V ) . NOTE : *Patients cohorts 1-5 receive peptide vaccine , cohort 6 . Blood sample collect pharmacokinetic immunologic analysis . After completion study therapy , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Histologic diagnosis unresectable Stage III IV melanoma . All melanomas regardless primary site disease allow Measurable unresectable melanoma least 1 measurable lesion base Immunerelated Response Criteria ( irRC ) Have fail least 1 chemotherapy regimen metastatic disease , treat 2 prior chemotherapy regimen HLAA*0201 positive determine deoxyribonucleic ( DNA ) allelespecific polymerase chain reaction ( PCR ) assay ; cohort 5 amendment 9 cohort 6 , HLA restriction Positive stain tumor tissue antibodies 1 following : human melanoma black 45 ( HMB 45 ) gp100 , NYESO1 , and/or MART1 Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Prior chemotherapy immunotherapy must complete least 4 week study drug administration , adverse event either return baseline stabilize Prior treat brain meningeal metastasis must without magnetic resonance imaging ( MRI ) evidence progression least 8 week immunosuppressive dos systemic steroid ( &gt; 10 mg/day prednisone equivalent ) least 2 week study drug administration Prior systemic radiation therapy must complete least 4 week study drug administration . Prior focal radiotherapy complete least 2 week study drug administration . No radiopharmaceutical ( strontium , samarium ) within 8 week study drug administration Immunosuppressive dose systemic medication , steroid absorb topical steroid ( dos &gt; 10 mg/day prednisone equivalent ) must discontinue least 2 week study drug administration Completed nitrosourea treatment least 6 week administration study drug Prior surgery require general anesthesia must complete least 2 week study drug administration . Surgery require local/epidural anesthesia must complete least 72 hour study drug administration patient recover . Screening laboratory value must meet following criterion : white blood cell ( WBCs ) ≥ 2000 cells/ µL neutrophils ≥ 1500 cells/ µL platelets ≥ 100 x 10^3/ µL hemoglobin ≥ 9.0 g/dL serum creatinine ≤ 2 mg/dL aspartic transaminase ( AST ) ≤ 2.5 x upper limit normal ( ULN ) without , ≤ 5 x ULN hepatic metastasis alanine transaminase ( ALT ) ≤ 2.5 x ULN without , ≤ 5 x ULN hepatic metastasis bilirubin ≤ 2 x ULN ( except patient Gilbert 's syndrome , must total bilirubin &lt; 3.0 mg/dL ) Females childbearing potential must : Agree use use reliable form contraception ( eg , oral contraceptive , intrauterine device , double barrier method condom spermicidal ) least 28 day prior first dose study drug , Treatment Period ( Treatment/Followup receive study drug ) , least 70 day last dose study drug ; negative serum βhuman chorionic gonadotropin ( βHCG ) Screening . Males must agree use male contraception Treatment Period least 180 day last dose study drug . Must read , understood , provide write informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization nature study fully explain Willing adhere study visit schedule prohibition restriction specify protocol History severe hypersensitivity reaction monoclonal antibody ( mAbs ) Systemic hypersensitivity Montanide ISA 51 VG vaccine component Prior malignancy active within previous 2 year except locally curable cancer apparently cure , basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ prostate , cervix breast Patients active autoimmune disease document history autoimmune disease , history syndrome require systemic steroid immunosuppressive medication , except patient vitiligo resolve childhood asthma/atopy Known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) Positive test hepatitis B virus surface antigen ( HBV SAg ) hepatitis C virus ribonucleic acid ( HCV RNA ) indicate active chronic infection Prior therapy antiPD1 , antiPDL1 , antiprogrammed deathligand2 ( PDL2 ) , anticytotoxic T lymphocyteassociated antigen 4 ( CTLA4 ) antibody ( antibody target T cell costimulation pathway ) Concurrent medical condition require use immunosuppressive medication , immunosuppressive dos systemic absorbable topical corticosteroid Underlying medical condition ( eg , condition associate diarrhea ) , Investigator 's opinion , would make administration either study drug study drug hazardous patient obscure interpretation toxicity determination adverse event Pregnant nursing Current participation another clinical study involve treatment medication , radiation surgery , prior participation study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IIIA melanoma</keyword>
	<keyword>stage IIIB melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>